Clinical trials: CRT Non-Response
Oncology, Biomarker
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
This non-interventional single-center explorative biomarker study aims at longitudinal comprehensive characterization (molecular genetics, immunological, morphological, image-based and microbial features) of the patient (host)…
- Conditions
- Oncology, Biomarker, NSCLC, Stage III, Durvalumab
- Trial name
- PRECISION (NCT05027165)
- Testing
- Non-interventional
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- LMU Klinikum
Cardiac Resynchronization Therapy, Non-LBBB, QRS Area
MARC-2: MARKERS AND RESPONSE TO CRT in Non-LBBB
The purpose of the MARC-2 study is to investigate the relation of the QRS area, determined by vectorcardiography, and response to Cardiac Resynchronization Therapy (CRT) in patients with a wide QRS complex and without a typical…
- Trial name
- MARC-2 (NCT04120909)
- Testing
- Cardiac resynchronization therapy
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Maastricht University Medical Center
Non Small Cell Lung Cancer Stage III, Immunotherapy
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy
The predictive value of the microbiome (throat swabs, stool and of bronchial samples) to identify patients who will relapse during durvalumab treatment after CRT (False negative Rate) at 6 months.
- Trial name
- Prediction (NCT04711330)
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 126 people
- Sponsor
- Leiden University Medical Center
Non Small Cell Lung Cancer
Lung Cancer With Copanlisib and Durvalumab
The current study focuses on unresectable stage III non-small cell lung cancer (NSCLC) patients who are starting Durvalumab consolidation after concurrent chemoradiation with a goal of cure.
- Trial name
- LCD (NCT04895579)
- Testing
- Durvalumab, Copanlisib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Zhonglin Hao
Non-small Cell Lung Cancer Stage III
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well.
- Trial name
- NCT02053285
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Lung Cancer, Lung Cancer Stage III
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
The introduction of maintenance immunotherapy with the anti PD-L1 inhibitor durvalumab opened a new therapeutic window for stage III NSCLC patients who achieve at least stable disease after chemo-radiation, as shown by the…
- Trial name
- NCT04364776
- Testing
- Durvalumab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Heart Failure With Reduced Ejection Fraction
Improving CRT Outcome With Non-Invasive Cardiac Mapping
The ICONIC-M study is a multicenter randomized controlled study to assess patient response to CRT comparing ECGI map guided left ventricular lead placement with empirical lead placement.
- Trial name
- ICONIC-M (NCT05564793)
- Testing
- Pre-implantation planning, Post-implantation assessment
- Where
- 11 sites in Netherlands, Portugal and 2 more
- Volunteers
- 330 people
- Sponsor
- EP Solutions SA
Heart Failure, Congestive, Cardiac Pacing, Artificial
Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.
Identifying \& optimizing strategies to reduce the burden of heart failure is vital. Despite advances in pharmacotherapy, patients with heart failure are at high risk for death \& hospitalization.
- Conditions
- Heart Failure, Congestive, Cardiac Pacing, Artificial, Defibrillators
- Trial name
- INCREMENTAL (NCT00399594)
- Testing
- A, B
- Where
- 3 sites in Canada
- Volunteers
- 96 people
- Sponsor
- University of Calgary
Heart Failure
Predicting Response to CRT Using Body Surface ECG Mapping
Cardiac resynchronization therapy (CRT) involves pacing the left and right side of the heart in order to improve the coordination of the contraction in patients with heart failure.
- Trial name
- NCT01831518
- Testing
- CRT Implant, Body Surface ECG Mapping
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Tom Jackson
Stage IIIA Non-small Cell Lung Cancer
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET)/computed tomography (CT) in predicting chemoradiation therapy (CRT) failure in patients with stage IIIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT01314677
- Testing
- positron emission tomography/computed tomography (PET/CT), fludeoxyglucose F 18
- Sponsor
- City of Hope Medical Center
Rectal Cancer Patients
Impact Of Metformin In Rectal Cancer Patients
Design: Prospective, randomized controlled clinical trial Setting: at Minia University Hospital and Minia Oncology Institute. Condition: Colorectal cancer.
- Trial name
- NCT06728982
- Testing
- Metformin
- Where
- 2 sites in Egypt
- Volunteers
- 85 people
- Sponsor
- Minia University
CRT Non-Response, LBBB
Left Ventricular Myocardial Work for Predicting Response to CRT
This study aims to establish the normal reference values for left ventricular myocardial work in healthy Chinese adults and the influencing factors.
- Conditions
- CRT Non-Response, LBBB, HF - Heart Failure, Healthy Adult
- Trial name
- CARE-MW (NCT07319065)
- Testing
- Ultrasound machine
- Where
- 82 sites in China
- Volunteers
- 3,240 people, healthy volunteers welcome
- Sponsor
- First Hospital of China Medical University
Heart Failure With Reduced Ejection Fraction
CPET Predicts Long-term Survival and Positive Response to CRT
The study tested the usefulness of cardiopulmonary exercise test (CPET) in selection of potential responders to CRT.
- Trial name
- CPET-CRT (NCT03870074)
- Volunteers
- 122 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Pancreatic Cancer
A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer
This study will observe side effects for patients who receive a 3-week course of radiation and chemotherapy for pancreas cancer.
- Trial name
- NCT03902600
- Testing
- Moderately Hypofractionated RT
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- Mayo Clinic
Esophageal Carcinoma
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
- Trial name
- NCT06549413
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
The purpose of this study is to determine whether [18F]-ML-10 used in conjunction with PET imaging is effective as an imaging tool for the early detection of response of oncological tumors in the lungs,head and neck to…
- Trial name
- NCT01260480
- Testing
- [18F]-ML-10 in conjunction with PET imaging
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aposense Ltd.
Esophageal Cancer
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
- Trial name
- NCT06414902
- Testing
- ArabinoFuranosylGuanine [18F]F-AraG
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms, Dual-Energy X-Ray Absorptiometry
Total Body Composition in Detection of Nutrition Depletion in Head and Neck Patients
The purpose of this study is to define the role of total body composition in the guidance of nutritional support and treatment monitoring in head and neck patients.
- Conditions
- Head and Neck Neoplasms, Dual-Energy X-Ray Absorptiometry, Malnutrition
- Trial name
- TBCHNC (NCT02854735)
- Testing
- Imaging by CT and densitometry
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chang Gung Memorial Hospital
Lung Neoplasm, Cell Hypoxia
Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy
Non-small cell lung cancer (NSCLC) has a poor prognosis if not caught early enough. One of the factors that may impact the ability to control NSCLC is low oxygen levels (hypoxia) inside the tumour.
- Trial name
- NCT00765986
- Testing
- 18F-FAZA, 18F-Fluorodeoxyglucose (18F-FDG)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- AHS Cancer Control Alberta
NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607.
- Conditions
- NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection, AJCC is Classified as IIA-IIIB
- Trial name
- NCT07534033
- Testing
- Probiotics combined with neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhujiang Hospital